Rezolute highlights Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism at ENDO meeting

Rezolute

Rezolute

RZLT

0.00
  • Rezolute highlighted previously reported Phase 3 sunRIZE results for ersodetug in congenital hyperinsulinism at the Endocrine Society meeting.
  • Deeper analyses reinforced a meaningful clinical benefit, supporting the drug’s late-stage profile in refractory hypoglycemia.
  • An expanded-access case series in tumor-related hyperinsulinism showed favorable outcomes, with 75% stopping IV dextrose/TPN support.
  • Natural history studies presented at the same meeting underscored the disease burden, strengthening the commercial rationale for ersodetug.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606170700PRIMZONEFULLFEED9748349) on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.